Cargando…

Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer

PURPOSE: To determine whether metastatic castration–resistant prostate cancers (mCRPC) partition into molecular phenotypes corresponding to intrinsic differentiation states and ascertain whether these subtypes exhibit specific druggable features and associate with treatment outcomes. EXPERIMENTAL DE...

Descripción completa

Detalles Bibliográficos
Autores principales: Coleman, Ilsa M., DeSarkar, Navonil, Morrissey, Colm, Xin, Li, Roudier, Martine P., Sayar, Erolcan, Li, Dapei, Corey, Eva, Haffner, Michael C., Nelson, Peter S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365375/
https://www.ncbi.nlm.nih.gov/pubmed/35552660
http://dx.doi.org/10.1158/1078-0432.CCR-21-4289
_version_ 1784765331446693888
author Coleman, Ilsa M.
DeSarkar, Navonil
Morrissey, Colm
Xin, Li
Roudier, Martine P.
Sayar, Erolcan
Li, Dapei
Corey, Eva
Haffner, Michael C.
Nelson, Peter S.
author_facet Coleman, Ilsa M.
DeSarkar, Navonil
Morrissey, Colm
Xin, Li
Roudier, Martine P.
Sayar, Erolcan
Li, Dapei
Corey, Eva
Haffner, Michael C.
Nelson, Peter S.
author_sort Coleman, Ilsa M.
collection PubMed
description PURPOSE: To determine whether metastatic castration–resistant prostate cancers (mCRPC) partition into molecular phenotypes corresponding to intrinsic differentiation states and ascertain whether these subtypes exhibit specific druggable features and associate with treatment outcomes. EXPERIMENTAL DESIGN: We used RNAseq, digital spatial profiling, and histological assessments from metastatic biopsies and patient-derived xenografts to segregate mCRPCs into subtypes defined by the PAM50 breast cancer classification algorithm. Subtype associations with treatment responses in preclinical models and patients were determined. RESULTS: Using the PAM50 algorithm, we partitioned 270 mCRPC tumors into LumA (42%), LumB (24%), and Basal (34%) subtypes with classification largely driven by proliferation rates and androgen receptor (AR) activity. Most neuroendocrine tumors classified as Basal. Pathways enriched in the LumA subtype include TGFß and NOTCH signaling. LumB subtype tumors were notable for elevated MYC activity. Basal subtype tumors exhibited elevated IL6-STAT3 signaling and features of adult stem cell states. In patients where multiple tumors were evaluated, the majority had concordant PAM50 subtype determination, though a subset exhibited marked inter- and intratumor heterogeneity, including divergent classifications between primary and metastatic sites. In preclinical models, LumA subtype tumors were highly responsive to androgen deprivation and docetaxel chemotherapy whereas Basal tumors were largely resistant. In clinical cohorts patients with Basal subtype tumors demonstrated a shorter time on treatment with AR signaling inhibitors and docetaxel relative to patients with luminal subtypes. CONCLUSIONS: Subtyping of mCRPC based on cell differentiation states has potential clinical utility for identifying patients with divergent expression of treatment targets and responses to systemic therapy.
format Online
Article
Text
id pubmed-9365375
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-93653752023-01-05 Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer Coleman, Ilsa M. DeSarkar, Navonil Morrissey, Colm Xin, Li Roudier, Martine P. Sayar, Erolcan Li, Dapei Corey, Eva Haffner, Michael C. Nelson, Peter S. Clin Cancer Res Translational Cancer Mechanisms and Therapy PURPOSE: To determine whether metastatic castration–resistant prostate cancers (mCRPC) partition into molecular phenotypes corresponding to intrinsic differentiation states and ascertain whether these subtypes exhibit specific druggable features and associate with treatment outcomes. EXPERIMENTAL DESIGN: We used RNAseq, digital spatial profiling, and histological assessments from metastatic biopsies and patient-derived xenografts to segregate mCRPCs into subtypes defined by the PAM50 breast cancer classification algorithm. Subtype associations with treatment responses in preclinical models and patients were determined. RESULTS: Using the PAM50 algorithm, we partitioned 270 mCRPC tumors into LumA (42%), LumB (24%), and Basal (34%) subtypes with classification largely driven by proliferation rates and androgen receptor (AR) activity. Most neuroendocrine tumors classified as Basal. Pathways enriched in the LumA subtype include TGFß and NOTCH signaling. LumB subtype tumors were notable for elevated MYC activity. Basal subtype tumors exhibited elevated IL6-STAT3 signaling and features of adult stem cell states. In patients where multiple tumors were evaluated, the majority had concordant PAM50 subtype determination, though a subset exhibited marked inter- and intratumor heterogeneity, including divergent classifications between primary and metastatic sites. In preclinical models, LumA subtype tumors were highly responsive to androgen deprivation and docetaxel chemotherapy whereas Basal tumors were largely resistant. In clinical cohorts patients with Basal subtype tumors demonstrated a shorter time on treatment with AR signaling inhibitors and docetaxel relative to patients with luminal subtypes. CONCLUSIONS: Subtyping of mCRPC based on cell differentiation states has potential clinical utility for identifying patients with divergent expression of treatment targets and responses to systemic therapy. American Association for Cancer Research 2022-07-15 2022-05-12 /pmc/articles/PMC9365375/ /pubmed/35552660 http://dx.doi.org/10.1158/1078-0432.CCR-21-4289 Text en ©2022 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle Translational Cancer Mechanisms and Therapy
Coleman, Ilsa M.
DeSarkar, Navonil
Morrissey, Colm
Xin, Li
Roudier, Martine P.
Sayar, Erolcan
Li, Dapei
Corey, Eva
Haffner, Michael C.
Nelson, Peter S.
Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
title Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
title_full Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
title_fullStr Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
title_full_unstemmed Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
title_short Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
title_sort therapeutic implications for intrinsic phenotype classification of metastatic castration-resistant prostate cancer
topic Translational Cancer Mechanisms and Therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365375/
https://www.ncbi.nlm.nih.gov/pubmed/35552660
http://dx.doi.org/10.1158/1078-0432.CCR-21-4289
work_keys_str_mv AT colemanilsam therapeuticimplicationsforintrinsicphenotypeclassificationofmetastaticcastrationresistantprostatecancer
AT desarkarnavonil therapeuticimplicationsforintrinsicphenotypeclassificationofmetastaticcastrationresistantprostatecancer
AT morrisseycolm therapeuticimplicationsforintrinsicphenotypeclassificationofmetastaticcastrationresistantprostatecancer
AT xinli therapeuticimplicationsforintrinsicphenotypeclassificationofmetastaticcastrationresistantprostatecancer
AT roudiermartinep therapeuticimplicationsforintrinsicphenotypeclassificationofmetastaticcastrationresistantprostatecancer
AT sayarerolcan therapeuticimplicationsforintrinsicphenotypeclassificationofmetastaticcastrationresistantprostatecancer
AT lidapei therapeuticimplicationsforintrinsicphenotypeclassificationofmetastaticcastrationresistantprostatecancer
AT coreyeva therapeuticimplicationsforintrinsicphenotypeclassificationofmetastaticcastrationresistantprostatecancer
AT haffnermichaelc therapeuticimplicationsforintrinsicphenotypeclassificationofmetastaticcastrationresistantprostatecancer
AT nelsonpeters therapeuticimplicationsforintrinsicphenotypeclassificationofmetastaticcastrationresistantprostatecancer